ICU Medical, Inc. (NASDAQ:ICUI) CEO Sells $213,474.04 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 1,373 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $16,262,119.64. This represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Vivek Jain also recently made the following trade(s):

• On Monday, December 2nd, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $162.91, for a total transaction of $1,954,920.00.
• On Friday, November 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00.

ICU Medical Stock Up 1.4 %

NASDAQ ICUI opened at $160.21 on Friday. ICU Medical, Inc. has a 52 week low of $86.80 and a 52 week high of $196.26. The firm has a market capitalization of $3.92 billion, a price-to-earnings ratio of -35.06 and a beta of 0.63. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The company has a fifty day moving average of $164.26 and a two-hundred day moving average of $156.05.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. KeyCorp upped their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Raymond James lifted their price target on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $199.67.

Institutional Trading of ICU Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC boosted its position in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 122 shares during the period. Allworth Financial LP boosted its stake in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of ICU Medical by 1,510.0% in the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 302 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in ICU Medical during the 2nd quarter valued at about $70,000. Finally, Canada Pension Plan Investment Board purchased a new stake in ICU Medical in the 2nd quarter valued at about $71,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.